S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
NASDAQ:CELC

Celcuity (CELC) Stock Price, News & Analysis

$17.43
+1.87 (+12.02%)
(As of 03/1/2024 ET)
Today's Range
$15.46
$17.45
50-Day Range
$13.74
$17.43
52-Week Range
$8.39
$17.45
Volume
392,465 shs
Average Volume
130,749 shs
Market Capitalization
$421.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00

Celcuity MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
72.1% Upside
$30.00 Price Target
Short Interest
Bearish
7.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of Celcuity in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$115,079 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.76) to ($2.84) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.81 out of 5 stars

Medical Sector

689th out of 947 stocks

Medical Laboratories Industry

16th out of 20 stocks


CELC stock logo

About Celcuity Stock (NASDAQ:CELC)

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

CELC Stock Price History

CELC Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Stifel Nicolaus Initiates Coverage on Celcuity (NASDAQ:CELC)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
Celcuity (NASDAQ: CELC)
Q3 2023 Celcuity Inc Earnings Call
Cancer research company Celcuity raises $50 million
See More Headlines
Receive CELC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
3/03/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:CELC
Fax
N/A
Employees
45
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.00
High Stock Price Target
$40.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+72.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-40,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.17 per share

Miscellaneous

Free Float
18,322,000
Market Cap
$421.81 million
Optionable
Optionable
Beta
0.74
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Brian F. Sullivan (Age 62)
    Co-Founder, Chairman & CEO
    Comp: $105.77k
  • Dr. Lance G. Laing Ph.D. (Age 62)
    Co-Founder, Chief Science Officer, VP, Secretary & Director
    Comp: $325.38k
  • Ms. Vicky Hahne (Age 58)
    Chief Financial Officer
    Comp: $210k
  • Dr. John R. MacDonald Dabt (Age 69)
    Ph., Ph.D., Senior Vice President of R&D
  • Ms. Sheri Smith
    Acting Head of Clinical Operations
  • Mr. Igor Gorbatchevsky M.D.
    Chief Medical Officer
  • Mr. Eldon C. Mayer III (Age 63)
    M.B.A., Chief Commercial Officer














CELC Stock Analysis - Frequently Asked Questions

Should I buy or sell Celcuity stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CELC shares.
View CELC analyst ratings
or view top-rated stocks.

What is Celcuity's stock price target for 2024?

3 brokers have issued 12 month price objectives for Celcuity's stock. Their CELC share price targets range from $23.00 to $40.00. On average, they expect the company's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 72.1% from the stock's current price.
View analysts price targets for CELC
or view top-rated stocks among Wall Street analysts.

How have CELC shares performed in 2024?

Celcuity's stock was trading at $14.57 on January 1st, 2024. Since then, CELC shares have increased by 19.6% and is now trading at $17.43.
View the best growth stocks for 2024 here
.

Are investors shorting Celcuity?

Celcuity saw a increase in short interest in February. As of February 15th, there was short interest totaling 1,780,000 shares, an increase of 30.9% from the January 31st total of 1,360,000 shares. Based on an average trading volume of 150,300 shares, the days-to-cover ratio is currently 11.8 days.
View Celcuity's Short Interest
.

When is Celcuity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our CELC earnings forecast
.

How were Celcuity's earnings last quarter?

Celcuity Inc. (NASDAQ:CELC) issued its quarterly earnings data on Monday, November, 13th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.09. During the same period in the prior year, the business posted ($0.75) EPS.

What other stocks do shareholders of Celcuity own?
When did Celcuity IPO?

(CELC) raised $18 million in an IPO on Wednesday, September 20th 2017. The company issued 2,000,000 shares at a price of $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

Who are Celcuity's major shareholders?

Celcuity's stock is owned by a number of institutional and retail investors. Top institutional investors include Commodore Capital LP (7.25%), Perceptive Advisors LLC (6.12%), Vanguard Group Inc. (3.39%), Northern Trust Corp (0.76%), PFM Health Sciences LP (0.65%) and UBS Group AG (0.22%). Insiders that own company stock include Brian F Sullivan, David Dalvey, Richard E Buller and Richard Nigon.
View institutional ownership trends
.

How do I buy shares of Celcuity?

Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CELC) was last updated on 3/3/2024 by MarketBeat.com Staff